Koers Nanoform Finland Oyj Nasdaq Helsinki
Aandelen
FI4000330972
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 7,48 mln. 8,13 mln. | Omzet 2025 * | 14,6 mln. 15,85 mln. | Marktkapitalisatie | 170 mln. 185 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -15 mln. -16,29 mln. | Nettowinst (verlies) 2025 * | -11 mln. -11,94 mln. | EV/omzet 2024 * | 17,6 x |
Nettoliquiditeiten 2024 * | 38,32 mln. 41,61 mln. | Nettoliquiditeiten 2025 * | 28,65 mln. 31,11 mln. | EV/omzet 2025 * | 9,7 x |
K/w-verhouding 2024 * |
-10,5
x | K/w-verhouding 2025 * |
-14,2
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 69,79% |
Recentste transcriptie over Nanoform Finland Oyj
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Edward Hæggström
CEO | Chief Executive Officer | 55 | 01-01-15 |
Albert Häggström
DFI | Director of Finance/CFO | 53 | 01-01-15 |
Investor Relations Contact | - | 01-05-19 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Chairman | 68 | 02-04-19 | |
Mads Laustsen
BRD | Director/Board Member | 67 | 01-01-19 |
Albert Häggström
DFI | Director of Finance/CFO | 53 | 01-01-15 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+39,69% | 54,04 mld. | |
+44,08% | 41,96 mld. | |
-1,43% | 41,92 mld. | |
-7,20% | 28,35 mld. | |
+12,32% | 26,35 mld. | |
-21,82% | 19 mld. | |
+7,22% | 13 mld. | |
+29,33% | 12,28 mld. | |
+25,53% | 12,19 mld. |